Learning Effective Clinical Treatment Pathways for Type-2 Diabetes

Rohit Vashisht

OHDSI Symposium
October 19-20, North Bethesda, MD, USA

STANFORD
SCHOOL OF MEDICINE

Guidelines versus Practice of Medicine in T2D





Jane E. B Reush & Joann Manson **JAMA** 2017

Hripcsak et al **PNAS** 2016

Learning Effective Treatment Pathways from Observational Data: *Analysis of over 103 million patients in 4 Countries*



Cohort Construction



Drug Efficacy – Sulfonylurea vs DPP4 Inhibitors



Replication at Other Sites & Meta-Analysis



Conclusion

- DPP4-Inhibitors appear to be more effective in reducing HbA1c of T2D patients
  - There is no detectable difference in events related to myocardial infarction, kidney- and eye-related disorders.
- OHDSI platform enables us to perform large-scale observational studies and assess their reproducibility.
  - If you have your data in OHDSI format then please participate in this study.

Thank You

rohitv@stanford.edu

Team - Stanford
- Nigam Shah
- Suzanne Tamang
- Alison Callahan
- Sarah Pool
- Juan M Banda
- Ken Jung
- Vladimir Polony
- Vibhu Agarwal
- Alejandro Schuler

Team - JnJ
- Patrick Ryan
- James Weaver
- Martijn Schuemie

Team - IMSQuintiles
- Mui Van Zandt
- Anthony Reckard
- Christian Reich

Team – Ajou University, Korea
- Rae Woong Park
- Young Gun
- Sanghyung Jin

Team – Cerner
- Hua Xu
- Yonghui Wu

Team – Mt. Sinai
- Li Li
- Joel. T Dudley

Team – Columbia
- Peng Jin
- Karthik Natrajan
- George Hripcsak
- Maura Beaton